Single High Dose of Brachytherapy Is Effective Against Prostate Cancer, Study Finds

Single High Dose of Brachytherapy Is Effective Against Prostate Cancer, Study Finds
A single high-dose brachytherapy treatment is as effective against localized prostate cancer as many low doses over time, and is safe, according to a study. The research, “Favorable Preliminary Outcomes for Men With Low- and Intermediate-risk Prostate Cancer Treated With 19-Gy Single-fraction High-dose-rate Brachytherapy,” was published in the International Journal of Radiation Oncology, Biology, Physics. Brachytherapy is a common form of radiation treatment against prostate cancer. It involves placing a sealed radiation source inside or next to a tumor, sparing adjacent healthy tissue. Reducing adjacent healthy tissues' exposure to radiation is particularly important in treating prostate tumors, because they are surrounded by key body structures. Doctors can administer either low doses or high doses of brachytherapy. Low-dose-rate (LDR) brachytherapy involves the permanent implanting of radioactive seeds in a tumor, where they release low levels of radiation for months. The high-dose-rate (HDR) therapy involves implanting a radiation seed for one treatment, then removing it. Patients usually receive HDR brachytherapy in four to nine treatment sessions, however -- not one. Although the number of sessions can be reduced by increasing the dose in each session, there are safety concerns. To start with, there is limited data about the toxicity of escalated brachytherapy doses. Now, researchers have found that patients who receive a single 19-Gy dose of HDR chemotherapy have similar outcomes as those receiving LDR brac
Subscribe or to access all post and page content.

Tagged , , , , .

Inês holds a PhD in Biomedical Sciences from the University of Lisbon, Portugal, where she specialized in blood vessel biology, blood stem cells, and cancer. Before that, she studied Cell and Molecular Biology at Universidade Nova de Lisboa and worked as a research fellow at Faculdade de Ciências e Tecnologias and Instituto Gulbenkian de Ciência. Inês currently works as a Managing Science Editor, striving to deliver the latest scientific advances to patient communities in a clear and accurate manner.

One comment

  1. Lawrence Glickman says:

    This is an imprecise treatment where the number and type of seeds vary greatly. In the past combined with exterior beam radiation for true “cures”. Patients with low to moderate lesions and low Gleeson scores as discussed here have a variety of better treatment options with few side effects. The Cyber knife folks just released a huge study for this type of patient with over 90% cure rates and extremely low side effects with radio beam computer controlled very high accuracy treatment. Like wise the new Toocad system completed with great results FDA 3 studies at Sloan Kettering and uses no radiation in a single procedure and should be FDA approved soon. Available in Mexico now and soon in the USA and Europe. In short Seeds are an old treatment that will soon be obsolete in my opinion. I am not a Doctor but a 15 year independent researcher due to deaths in my family and mentoring from the former founder of the PCRI center in Los Angeles.

Leave a Comment

Your email address will not be published. Required fields are marked *